Charlotte Schubert is a Science Writer and Reporter based in Seattle. She specializes in topics related to health and medical research, often exploring the intersection of science and technology. Charlotte's work has been featured in prominent outlets such as BMJ, Medical Xpress, and GeekWire.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
United States (National)
Not enough data
Not enough data
Charlotte Schubert's coverage predominantly focuses on the local tech and biotech sectors, particularly in Seattle. She heavily features press releases and private sector announcements related to biotechnology, medical research, startups, and AI developments within the region. Pitches for her should highlight new scientific breakthroughs, innovations in technology or business strategies from local companies or institutions.
Given her focus on specific businesses and their announcements, she may be interested in pitches that offer exclusive insights into these companies' future plans or recent developments. Additionally, experts with a strong understanding of the Seattle business landscape would likely appeal to Charlotte.
This information evolves through artificial intelligence and human feedback. Improve this profile .
A new four-drug combination is highly effective and safe in patients with newly diagnosed multiple myeloma, according to data presented at the annual meeting of the American Society of Clinical Oncology
By: Charlotte Schubert
Researchers at Sylvester are investigating a mutation linked to colorectal and endometrial cancer, in the gene encoding XPO1.
Justin Taylor, M.D., a physician-scientist at Sylvester Comprehensive Cancer Center, part of the University of Miami Miller School of Medicine, has released a preclinical study highlighting a potential new way to treat colorectal cancer. The findings appear in Cancer Research.
By: Charlotte Schubert
A new Sylvester Comprehensive Cancer Center study should expand the donor pool for patients who have trouble finding a perfect match.
By: Charlotte Schubert
TAF1 activates genes that prompt blood cell maturation from stem cells, suggests a study led by Sylvester Director Dr. Stephen D. Nimer.
By: Charlotte Schubert
The drug olutasidenib targets a mutation linked to some cases of MDS, a potentially deadly condition that can progress to leukemia.
By: Charlotte Schubert, Leonard M. Miller
A new study led by Stephen D. Nimer, M.D., director of Sylvester Comprehensive Cancer Center, part of the University of Miami Miller School of
By: Heinrich Heine, Tim Hagenacker, Jana Zschüntzsch, Sven G. Meuth, Sarah Hoffmann, Andreas Totzeck, Justus Liebig, Charlotte Schubert, Valerie Scherwietes, Sophie Lehnerer, Thomas Skripuletz, Translational Neuro
Abstract Objective This study examined whether the timing of targeted add-on therapy initiation influences clinical outcomes in acetylcholine
